No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ANAB250117P15000
- 1.65
- +0.15+10.00%
15min DelayClose Dec 23 16:00 ET
1.65High1.50Low
1.50Open1.50Pre Close10 Volume2.35K Open Interest15.00Strike Price1.58KTurnover72.84%IV4.44%PremiumJan 17, 2025Expiry Date1.03Intrinsic Value100Multiplier24DDays to Expiry0.62Extrinsic Value100Contract SizeAmericanOptions Type-0.6074Delta0.1473Gamma8.47Leverage Ratio-0.0199Theta-0.0058Rho-5.14Eff Leverage0.0139Vega
Intraday
- 5D
- Daily
News
Shareholders in AnaptysBio (NASDAQ:ANAB) Have Lost 60%, as Stock Drops 13% This Past Week
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41